10x Genomics, Inc.TXG
ASignal's systematic analysis rates TXG as Bullish.
Reflects the latest available analysis · analyzed Aug 20, 2026
The case on TXG
Bull vs bear, surfaced by ASignal's framework agents from public market data. The precise verdict: ASignal Rank, confidence, and price targets - is in the app.
- Strong gross margin (70.11%) indicating pricing power
- High cash position ($552.03M) and low debt-to-equity (0.10x)
- Positive free cash flow ($179.66M)
- Current ratio of 5.69x suggests strong liquidity
- MACD above signal line with expanding histogram, confirming upward momentum
- RSI at 75.66 indicates overbought conditions
- Negative net and operating margins (-12.18%, -15.20%)
- Negative ROE (-9.40%) and ROA (-5.05%)
- EV/EBITDA at -185.18x due to negative earnings
- Year-over-year revenue decline of 12.70%
- Forward P/E of 312.94x suggests high valuation risk
See the full verdict on TXG
ASignal Rank (1-4), confidence score, Buffett / Ackman / Dalio grades, price targets, and the full reasoning behind the call.
How ASignal analyzes TXG
Most investors never get a second opinion, let alone several. ASignal runs TXG past a panel of specialized investor-framework agents, each calibrated on a distinct school of investing: Warren Buffett's value discipline, Bill Ackman's activist lens, and Ray Dalio's macro view. They don't just score in isolation, they argue: a dedicated Challenger agent pushes back on every conclusion until the panel settles on a reasoned consensus, weighing fundamentals, macro conditions, market sentiment, and price action together. The kind of cross-examined read that takes a research desk hours, ASignal delivers in under two minutes, refreshed every cycle.
The signal direction and the bull and bear case above are free. The precise read, ASignal Rank, framework grades, price targets, and full reasoning, stays with subscribers.